What does the evidence say about other nutraceuticals?

A shelf with dividers, not one supplement answer

Most evidence in this group concerns adding a specific product to antidepressant treatment. It does not show that supplements work as a class or that these products can replace psychotherapy or medication.

Product identity matters. A result for one folate form, dose, or combination does not automatically transfer to a related chemical or a store product with a similar name.

The clearest bounded role

L-methylfolate. This has the clearest clinical position in the package: a second-line adjunct with small average effects. That is a real but limited role, not a transformative or first-choice treatment.

It is not interchangeable with ordinary folic acid or folinic acid. The evidence belongs to the tested form and dose.

Weaker and limited leads

SAMe. Earlier studies and reviews were more favorable, but newer randomized trials were mixed. Current guidance places it later, as a third-line adjunct rather than the stronger position it once held.

No dependable effect size can be promised. Bipolar-spectrum history matters because mood switching is a concern, so psychiatric and medication review belong to the decision.

Vitamin D. Two positive adjunctive studies created a limited lead, not a stable treatment estimate or routine augmentation role. Treating a documented vitamin D deficiency is a separate medical question from giving vitamin D as an antidepressant to unselected adults.

High doses can cause harm, including high calcium levels. Dose, current levels, other supplements, and relevant medical history may require review and monitoring.

Isolated or mixed findings

Folinic acid. One isolated positive finding. It is distinct from L-methylfolate and folic acid and does not have a routine clinical role.

Creatine. One promising finding does not establish a routine adjunctive role or apply to every creatine product, dose, and population.

Amino-acid combinations. A positive combination study cannot show which ingredient contributed or whether any ingredient works alone.

Zinc and vitamin C. Results were inconsistent. Neither has a stable antidepressant claim, and there is no evidence-based way to identify in advance who would respond. Treating a documented deficiency is a separate question. High-dose zinc can cause copper deficiency.

Tryptophan and 5-HTP. Findings were inconsistent, and the two agents should not be collapsed into one positive category. Both can create serotonergic interaction concerns, especially alongside serotonergic medicines.

Mixed and isolated findings do not automatically become recommendations. Small, short studies also do not justify one broad “generally safe” statement for every product, dose, and duration.

Where the evidence did not earn a seat

Folic acid. Ordinary folic acid did not show a reliable pooled benefit. It should not inherit L-methylfolate’s claim simply because both are described as forms of folate.

Inositol. Adjunctive studies did not find significant benefit. That is not a complete long-term safety evaluation, but it does mean the accepted evidence does not support an antidepressant add-on role.

What trying one actually involves

A nutraceutical trial can add cost, pill burden, interaction checks, uncertainty about commercial quality, and sometimes laboratory monitoring. Where benefit exists, it is generally small or uncertain and usually measured as a change in symptom ratings rather than durable recovery or functioning.

The right starting point is not “Which supplement stack should I buy?” It is “What specific problem are we trying to solve, and does this exact formulation have evidence for that role?”

Severe or high-risk depression should not be redirected into supplement experimentation or delayed indicated care.